title: Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.
abstract: In the present study we evaluated the protection raised by immunization with recombinant influenza viruses carrying sequences coding for polypeptides corresponding to medial and carboxi-terminal moieties of Trypanosoma cruzi ´s amastigote surface protein 2 (ASP2). Those viruses were used in sequential immunization with recombinant adenovirus (heterologous prime-boost immunization protocol) encoding the complete sequence of ASP2 (Ad-ASP2) in two mouse strains (C57BL/6 and C3H/He). The CD8 effector response elicited by this protocol was comparable to that observed in mice immunized twice with Ad-ASP2 and more robust than that observed in mice that were immunized once with Ad-ASP2. Whereas a single immunization with Ad-ASP2 sufficed to completely protect C57BL/6 mice, a higher survival rate was observed in C3H/He mice that were primed with recombinant influenza virus and boosted with Ad-ASP2 after being challenged with T. cruzi. Analyzing the phenotype of CD8+ T cells obtained from spleen of vaccinated C3H/He mice we observed that heterologous prime-boost immunization protocol elicited more CD8+ T cells specific for the immunodominant epitope as well as a higher number of CD8+ T cells producing TNF-α and IFN-γ and a higher mobilization of surface marker CD107a. Taken together, our results suggest that immunodominant subpopulations of CD8+ T elicited after immunization could be directly related to degree of protection achieved by different immunization protocols using different viral vectors. Overall, these results demonstrated the usefulness of recombinant influenza viruses in immunization protocols against Chagas Disease.
authors: Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brasil.
authors: Rafael Polidoro Alves
authors: RP
authors: Barbosa
authors: Bruno Galvão
authors: BG
authors: Filho
authors: Luara Isabela
authors: LI
authors: Dos Santos
authors: Policarpo Ademar Sales
authors: PA
authors: Junior
authors: Pedro Elias
authors: PE
authors: Marques
authors: Rafaela Vaz Sousa
authors: RV
authors: Pereira
authors: Denise Carmona
authors: DC
authors: Cara
authors: Oscar
authors: O
authors: Bruña-Romero
authors: Maurício Martins
authors: MM
authors: Rodrigues
authors: Ricardo Tostes
authors: RT
authors: Gazzinelli
authors: Alexandre Vieira
authors: AV
authors: Machado
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000276:immunology; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002460:Cell Line; D014355:Chagas Disease / Q000276:immunology / Q000401:mortality / Q000469:parasitology / Q000517:prevention & control*; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D051379:Mice; D009439:Neuraminidase / Q000276:immunology*; D009975:Orthomyxoviridae / Q000235:genetics / Q000276:immunology; D010641:Phenotype; D016052:Protozoan Vaccines / Q000235:genetics / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D014349:Trypanosoma cruzi / Q000235:genetics / Q000276:immunology*; D014611:Vaccination
chemical_list: D000913:Antibodies, Protozoan; D018984:Epitopes, T-Lymphocyte; D007074:Immunoglobulin G; D016052:Protozoan Vaccines; C493236:ASP-2 protein, Trypanosoma cruzi; D009439:Neuraminidase
references: Virology. 2003 Aug 15;313(1):235-49
references: 12951036
references: Infect Immun. 2003 May;71(5):2744-57
references: 12704149
references: Expert Rev Vaccines. 2009 May;8(5):577-92
references: 19397415
references: Curr Opin Immunol. 2009 Jun;21(3):346-51
references: 19500964
references: PLoS One. 2012;7(4):e34445
references: 22529915
references: Expert Rev Vaccines. 2007 Apr;6(2):255-66
references: 17408374
references: Infect Immun. 2005 Sep;73(9):6017-25
references: 16113322
references: Am J Pathol. 2001 Nov;159(5):1723-33
references: 11696433
references: J Clin Invest. 1998 Sep 1;102(5):1062-71
references: 9727076
references: Front Immunol. 2012 Dec 04;3:358
references: 23264773
references: Virus Res. 2011 Dec;162(1-2):19-30
references: 21963677
references: J Immunol. 1998 Feb 15;160(4):1817-23
references: 9469442
references: PLoS Pathog. 2012;8(5):e1002699
references: 22615561
references: J Immunol. 2010 Jul 1;185(1):560-8
references: 20530265
references: Acta Trop. 2010 Jul-Aug;115(1-2):22-7
references: 19646412
references: Parasitol Int. 2008 Mar;57(1):38-48
references: 17728174
references: J Virol. 2001 Oct;75(19):8899-908
references: 11533153
references: Infect Immun. 2006 Apr;74(4):2477-81
references: 16552083
references: Histol Histopathol. 2002;17(3):837-44
references: 12168794
references: Virol J. 2011 Mar 18;8:127
references: 21418577
references: Immunol Rev. 1999 Aug;170:29-38
references: 10566139
references: Antiviral Res. 2012 May;94(2):168-78
references: 22504097
references: Expert Rev Mol Med. 2010 Sep 15;12:e29
references: 20840799
references: Curr Opin Infect Dis. 2011 Oct;24(5):428-34
references: 21857512
references: Int J Parasitol. 2010 Nov;40(13):1549-61
references: 20620143
references: An Acad Bras Cienc. 2003 Dec;75(4):443-68
references: 14605680
references: PLoS One. 2009;4(4):e5139
references: 19357780
references: PLoS Pathog. 2012;8(4):e1002645
references: 22532799
references: J Exp Med. 2007 Sep 3;204(9):2187-98
references: 17709425
references: Curr Top Microbiol Immunol. 2009;333:165-76
references: 19768405
references: Clin Microbiol Rev. 2011 Oct;24(4):655-81
references: 21976603
references: Infect Immun. 2002 Oct;70(10):5547-55
references: 12228281
references: Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:288-94
references: 19753487
references: Virology. 2006 Feb 5;345(1):73-87
references: 16271378
references: Int J Exp Pathol. 2010 Feb;91(1):72-86
references: 19878357
references: Lancet. 2010 Apr 17;375(9723):1388-402
references: 20399979
references: Annu Rev Immunol. 1999;17:51-88
references: 10358753
references: Infect Immun. 2009 Oct;77(10):4383-95
references: 19651871
references: Eur J Immunol. 2003 Jan;33(1):70-8
references: 12594834
references: Vaccine. 2012 Apr 16;30(18):2882-91
references: 22381075
references: Immunol Rev. 2011 Jan;239(1):237-70
references: 21198676
references: J Immunol. 1976 Mar;116(3):755-60
references: 815433
references: Vaccine. 2009 Oct 19;27(44):6154-9
references: 19712768
references: J Immunol. 2012 Jan 15;188(2):649-60
references: 22156594
references: Adv Parasitol. 2011;75:121-46
references: 21820554
references: PLoS Negl Trop Dis. 2012;6(4):e1598
references: 22509418
references: Scand J Immunol. 2007 Aug-Sep;66(2-3):297-308
references: 17635807
references: J Immunol. 2013 Jan 1;190(1):296-306
references: 23197262
references: Rev Soc Bras Med Trop. 2003 Mar-Apr;36(2):201-9
references: 12806455
references: J Virol. 2011 Nov;85(21):11468-78
references: 21865377
references: Vaccine. 2010 Apr 19;28(18):3247-56
references: 20189485
references: Hum Gene Ther. 2006 Apr;17(4):415-26
references: 16610929
references: Immunol Today. 2000 Apr;21(4):163-5
references: 10740236
references: Hum Gene Ther. 2006 Sep;17(9):898-908
references: 16972758
references: PLoS One. 2011;6(7):e22011
references: 21779365
references: J Virol. 1999 Nov;73(11):9679-82
references: 10516084
references: Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11531-6
references: 20534532
references: Curr Opin Infect Dis. 2001 Dec;14(6):733-41
references: 11964893
references: Mol Ther. 2008 Sep;16(9):1609-16
references: 18612271
references: Immunity. 2009 Feb 20;30(2):218-27
references: 19200758